A high-performance liquid chromatographic method was developed for simultaneous determination of four ACE-inhibitors: captopril (CAP), perindopril erbumine (PER), moexipril hydrochloride (MOEX), and ramipril (RAM) in pharmaceutical formulations.
Introduction
Angiotensin-converting enzyme (ACE) inhibitors are effective in the treatment of several medical conditions as hypertension (HT), congestive heart failure (CHF), post-myocardial infarction (MI), and diabetic nephropathy (Opie et al 1994 ., Wong et al 2004 that exhibit their antihypertensive effect by restraining the formation of angiotensin II (A II).
These compounds competitively antagonize ACE, the rate-limiting enzyme in the formation of A II, and angiotensin receptor blockers, which block the binding of A II to its receptor in the reninangiotensin-aldosterone neurohormonal system (RAAS). Besides this antihypertensive effect, the ACE inhibitors possess some additional properties (such as vasculoprotective and antithrombotic activities) that can play a favorable role in terms of cardiovascular morbidity (Okrucka et al 1998 ., Remkova et al 2000 .
The first ACE inhibitor developed was captopril, a thiol-containing compound. The discovery of captopril was followed by enalapril, a compound that lacked the thiol group and the potentially related side effects. The tremendous therapeutic and commercial success of captopril and enalapril has fueled extensive research activity in this field of medicinal chemistry with the preference to develop nonthiolcontaining ACE inhibitors (Opie et al 1994) .
ACE inhibitors for medicinal use are currently classified into three classes. The first class represents thiol-containing ACE inhibitors (captopril, zofenopril, omapatrilat) . To the second, and largest, class belong the dicarboxyl containing ACE inhibitors (perindopril, moexipril, ramipril, trandolapril, quinapril, benazepril, and cilazapril) .
The third class represents phosphorus containing inhibitors (fosinopril). It is well documented that the ACE inhibitors differ only moderately with respect to their pharmacodynamic efficacies (Gotti et al 2000) .
Until now, capillary electrophoresis was the major technique used for simultaneous determination of some ACE-inhibitors (Gotti et al 2000 ., Hillaert 2002 , other techniques as Gas chromatography (Ereda et al 1993) , HPTLC (Kowalczuk et al 2004 ., Wyszomirska et al 2010 , and flow injection assembly for rapid analysis of some ACE-inhibitors (Emara et al 2003) show peak splitting owing to slow cis-trans isomerization, caused by hindered rotation around the N-substituted peptide bond (Gustafsson et al 1990) .
In spite of the separation was tried using the columns and mobile phase previously described in literature, Beside that the proposed method can applied for assay of the drugs in presence of co-administered drug like hydrochlorothiazide, indapamide, atenolol . For this purpose, the influence of column type, mobile phase composition, buffer type, buffer pH and flow rate was systematically investigated and the method validation studies were performed.
Materials and methods

Instrumentation and chromatographic conditions
The HPLC (Shimadzu, Kyoto, Japan) instrument was The mobile phase was prepared by mixing methanol and 10 mM ammonium acetate; pH was adjusted to 6.0 using acet ic acid in a ratio (40: 60, v/v) . The flow rate was set at 1 ml min -1 . The detector was set at 210
nm. All determinations were performed at ambient temperature and the injection volume was 20 μL.
Operation, Data acquisition, and analysis were performed using Class-VP software. 
Materials and reagents
All solvents 
Standard solution
Stock solution of the cited drugs (1 mg ml -1 ) prepared by dissolving 25 mg each drug separately in 25 ml of methanol. The solutions were stable for one month (one week for captopril) when stored in refrigerator at 4 0 C
Preparation of calibration curve
The working solution was prepared separately by further dilution of the stock standard solution with the mobile phase to reach the concentration range of 5-50 µg ml -1 for the four drugs. Triplicate 20 µL injections were made for each concentration and chromatographed under the specified chromatographic conditions described previously.
The peak area of each drug was plotted against corresponding concentrations, linear relationship was obtained.
Sample preparation
Ten tablets of the four drugs (Table1) were weighed and finely powdered. A portion of the powder equivalent to 25 mg of each drug was accurately weighed, transferred separately to 25 ml volumetric flask, and dissolved in 25 ml methanol using ultrasonic bath (30 min) and then filtered through 0.45 um membrane filters (Millipore, Milford, MA).
Further dilution was carried out with mobile phase to reach calibration range of each compound.
Results and discussion
In order to validate an efficient method for analysis of drug in pharmaceutical formulations, preliminary test was performed with the objective to select adequate and optimum conditions. Parameters, such as type of column, ideal mobile phase and their proportions, optimum pH, flow rate, detection wave length, ionic strength the buffer were exhaustively studied.
A reversed phase high performance chromatography of these drugs, containing a proline or proline related residue, may show peak splitting owing to slow cis- trans isomerization, caused by hindered rotation around the N-substituted peptide bond (Gustafsson et al 1990) . Therefore, with a view to providing practical method suitable for reliable quality control of ACE-inhibitors, this study was concerned with the development of HPLC method able to avoid peak splitting and band broadening.
Three columns were used for simultaneous determination of the studied drugs namely; C18, C8, CN columns. Both C18 and C8 gave better peak shape and inadequate separation at low pH, and better resolution with peak splitting and band broadening at high pH. The better resolution and peaks shape without excessive tailing was obtained when applied the cynopropyl column.
Variation of pH of the ammonium acetate buffer result in maximum capacity factor (k / ) value at PH 6.0, with better shape and reasonable retention time.
At pH from 2.5-5.5 the drugs more retained and the peaks eluted very broadening, splitting, and with 
System suitability
The system suitability parameters including capacity factor (k / ), selectivity (α), resolution (Rs), tailing factor (T), and theoretical plate (N) listed in Table 2 . All parameters were satisfactory with good specificity for the assessment of captopril, perindopril, ramipril, and moexipril.
Analysis of pharmaceutical formulations
The proposed method was successfully applied to Table 3 showed that the t and F values were smaller than the critical values indicating that there was no significant difference between the proposed and published methods.
Ayad et al 2003). The results in
Validation of the method
Linearity
The linearity of the proposed method for determination of captopril, perindopril moexipril, 
Precision
For evaluation of the precision estimates, repeatability and intermediate precision were
performed at three concentration levels (5, 30, 50 µg ml -1 ) for each drug. The precision expressed as relative standard deviation (RSD %) of the mean measured concentration. Within the examined range, the intra-day reproducibility of the assay was 
Selectivity
The selectivity of the proposed method was evaluated through the possible interference due to excipients presented in pharmaceutical formulation. For that, placebo of each tablet sample was prepared by was investigated and no interference was observed with the proposed methods.
Accuracy
This study was performed by adding known amounts of the studied drug compound to known concentration of the commercial pharmaceutical tablet (standard addition method). The resulting mixtures were analyzed and the results obtained were compared with the expected results (Table 5) suggested the good accuracy of the proposed methods. The mean results ± SD from six determinations were 100.97 ± 0.90, 99.41 ± 0.55, 99.92 ± 0.88, and 100.72 ± 0.83 for captopril, moexipril, perindopril, and ramipril, respectively, indicative of the high accuracy of the method.
Robustness
Robustness is the measure of capacity of analytical methods to remain unaffected by small but deliberating variations of the operation parameters.
Variation of the pH of 10 mM ammonium acetate of the mobile phase by ± 0.2, organic solvent strength of the mobile phase by ± 2 %, and detector wavelength by ± 2 nm did not have significant effect on chromatographic resolution of in HPLC method.
Analyses were carried out in triplicate and only one parameter was changed in the experiments at a time.
The determination of 25 µg ml -1 for CAP, PER, RAM, and MOEX under the various conditions was performed. Each mean value was compared with the mean value obtained by optimum conditions. The statistically comparison was done with t test (Miller 1993) and no difference was found between results (p = 0.05). Therefore, the method is robust to the small changes in experimental conditions.
Solutions stability
In order to demonstrate the stability of both standard working solutions and tablets sample solutions during analysis, both solutions were analyzed over a period of 12 h at room temperature. The results showed that, the retention time and peak area of the cited drugs remained almost unchanged and no significant degradation was observed within the indicated period, suggesting that both solutions were stable for at least 12 h, which was sufficient for the whole analytical process.
Conclusion
An isocratic RP-LC method has been developed and validated for evaluation of ACE-inhibitors and their determination in bulk drugs and pharmaceuticals dosage forms simultaneously. The developed method has been found to be selective, sensitive, and precise.
The shorter duration of analysis for cited drugs makes these reported methods suitable for routine quantitative analysis in pharmaceutical dosage forms.
The method is capable of detecting 0.02 -0.09 μg ml-1 of the studied drugs making it successfully applied for clinical routine monitoring and pharmacokinetic studies of ACE-inhibitors.
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